PER-017-03Completed未知
HIV TREATMENT PROTOCOL WITH PEG-INTRON: STUDY SUB-STUDY P00737 AND STUDY P00738
Trial Snapshot
- Phase
- 未知
- Status
- Completed
Study Overview
Brief Summary
No summary available.
Study Design
- Study Type
- Interventional
Eligibility Criteria
Inclusion Criteria
- •Subjects must receive a HAART regimen at present.
- •The following laboratory parameters must be met:
- •Platelet count> 75,000/mm3
- •Hemoglobin> 9 gm / dl
- •Absolute neutrophil count> 1,000/mm3
- •Creatinine <1.5 times the upper limit of normal
- •SGOT / SGPT <5 times the normal upper limit
Exclusion Criteria
- •People who are participating in clinical studies of drugs currently in research, or have done so in the previous month.
- •Subjects with a history of hypersensitivity to interferons.
- •Subjects with a history of moderate or severe depression, dementia, or other major psychiatric conditions that require medical treatment.
Investigators
Similar Trials
Completed
Phase 2
Safety and Effectiveness of PEG-Intron in HIV-Infected PatientsHIV InfectionsNCT00005012Schering-Plough250
Completed
Not Applicable
PHASE III STUDY OF PEG-INTRON IN PATIENTS INFECTED BY HIV WHO HAVE EXPERIENCED MULTIPLE TREATMENTSPER-032-02SCHERING PLOUGH RESEARCH INSTITUTE,
Recruiting
Not Applicable
Clinical investigation of HIV infection diagnostic kitHIV infectionJPRN-UMIN000021201Keio University School of Medicine Center for Infectious Disease and Infection Control200
Active, not recruiting
Phase 1
A study of the effect of antiretroviral therapy and immunoglobulin on the HIV reservoir in Acute HIV Infection.Acute HIV InfectionMedDRA version: 14.1 Level: LLT Classification code 10000811 Term: Acute infection with HIV System Organ Class: 10021881 - Infections and infestationsEUCTR2011-001982-42-GBGuy's & St. Thomas' NHS Foundation Trust10
Active, not recruiting
Not Applicable
Maraviroc and cardiovascular risk in HIV+ patients.HIV-1 infection.EUCTR2014-002134-31-ITOspedale L. Sacco - Azienda Ospedaliera-Polo Universitario